Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Home
Rob Pieters

Rob Pieters

Pediatric oncologist

Pieters group

Phone 088 97 28 589

Email R.Pieters@prinsesmaximacentrum.nl

Implementation of paediatric precision oncology into clinical practice
- nov. 2022
- Karin P.S., Langenberg, et al
- European Journal of Cancer
Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
- sep. 2022
- Inge M., van der Sluis, et al
- British Journal of Haematology
MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus
- jul. 2022
- Kirsten, Canté-Barrett, et al
- JCI Insight
Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort
- mei 2022
- , et al
- Cancer investigation
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
- apr. 2022
- Linde, Dekker, et al
- Blood advances

View all publications

Rob Pieters

Publications

Implementation of paediatric precision oncology into clinical practice

Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus

Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia